A research paper has been published on CHO-MK, a novel host cell line for biopharmaceutical manufacturing developed by Chitose Laboratory Corp. (hereinafter, CHITOSE) after more than 10 years of research.

CHO-MK has been established from the primary cell culture of Chinese hamster ovary tissue, and was designed for industrial applications in biopharmaceutical production. The newly published paper details the establishment process of CHO-MK and discusses its high potential as a host cell line for biopharmaceutical production.

Using CHO-MK and the proprietary Chitose Super CHO™ (CS CHO)™ vector expression system, Chitose provides a Cell Line Development service for generation of research master cell banks that highly express recombinant proteins of interest (antibody productivity of 10 g/L has been achieved in just 5 days). 

➤Stable Cell Line Development Service for Biopharmaceutical Production

The publication marks significant academic recognition of CHO-MK, and we hope it will accelerate its adoption as a major host cell line for large-scale biopharmaceutical production. CHITOSE will continue to advance global medicine by developing next-generation biopharmaceutical manufacturing platforms based on CHO-MK.

* The establishment of CHO-MK was supported by AMED under the Grant Number JP18ae0101054.

Publication Information:
Date of Publication: June 2024 (accepted on February 18th, 2024; available online since March 12th, 2024）
Title: Establishment of a novel cell line, CHO-MK, derived from Chinese hamster ovary tissues for biologics manufacturing
Published in: Journal of Bioscience and Bioengineering
URL: https://doi.org/10.1016/j.jbiosc.2024.02.005

Related Information:
Stable Cell Line Development Service for Biopharmaceutical Production
MYCENAX and Chitose Laboratory Corp. to Scale-Up Production and Strengthen Marketing Activities for CHO-MK Cells